Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Clinical Trial of Photodynamic Diagnosis for Malignant Brain Glioma With 5-Aminolevulinic Acid

NCT06417281 is registered in ClinicalTrials.gov with Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT06417281
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06417281 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Clinical Trial of Photodynamic Diagnosis for Malignant Brain Glioma With 5-Aminolevulinic Acid
Lead sponsor
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
June 19, 2024
Completion date
August 19, 2025
Enrollment
86 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

5-aminolevulinic acid, malignant glioma of brain